XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.1
License Agreements - Novartis (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 149 Months Ended
Nov. 30, 2009
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2022
Dec. 31, 2021
License agreements          
Revenues   $ 733,235 $ 604,718    
JAKAFI          
License agreements          
Revenues   544,464 465,710    
Novartis          
License agreements          
Royalties payable   162,100   $ 162,100 $ 148,100
Novartis | Development Milestones          
License agreements          
Amount recognized and received for the achievement of a predefined milestone       157,000  
Novartis | Development Milestones | Maximum          
License agreements          
Upfront and immediate milestone payment to be received under license agreement $ 174,000        
Novartis | Regulatory Milestones          
License agreements          
Amount recognized and received for the achievement of a predefined milestone       280,000  
Novartis | Regulatory Milestones | Maximum          
License agreements          
Upfront and immediate milestone payment to be received under license agreement 495,000        
Novartis | Commercialization Milestones          
License agreements          
Amount recognized and received for the achievement of a predefined milestone       $ 200,000  
Novartis | Commercialization Milestones | Maximum          
License agreements          
Upfront and immediate milestone payment to be received under license agreement 500,000        
Novartis | TABRECTA          
License agreements          
Revenues   3,500 2,000    
Novartis | GVHD | Development and Regulatory Milestones | Maximum          
License agreements          
Upfront and immediate milestone payment to be received under license agreement $ 75,000        
Novartis | JAKAFI | U.S.          
License agreements          
Royalties payable on net sales   21,700 17,800    
Novartis | JAKAVI | Non-U.S.          
License agreements          
Revenues   $ 70,800 $ 65,600    
Novartis | JAKAVI | Minimum          
License agreements          
Royalty payments on future global net sales (as a percent)   12.00%      
Novartis | JAKAVI | Maximum          
License agreements          
Royalty payments on future global net sales (as a percent)   14.00%